Compare AMCI & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AMCI | MSLE |
|---|---|---|
| Founded | 2021 | N/A |
| Country | United States | Canada |
| Employees | N/A | 17 |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.4M | 146.9M |
| IPO Year | N/A | N/A |
| Metric | AMCI | MSLE |
|---|---|---|
| Price | $5.11 | $7.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 41.3K | 35.8K |
| Earning Date | 04-20-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.60 | $5.50 |
| 52 Week High | $15.75 | $13.39 |
| Indicator | AMCI | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 35.53 | 46.47 |
| Support Level | $5.07 | $6.73 |
| Resistance Level | $7.20 | $8.59 |
| Average True Range (ATR) | 0.44 | 0.63 |
| MACD | -0.16 | -0.03 |
| Stochastic Oscillator | 11.64 | 19.65 |
AMC Robotics Corp is a technology solutions company that offers AI-powered smart security and robotics solutions. It currently sells smart hardware products designed for residential and commercial use, including smart cameras, driving recorders, action cameras, and Retina K cameras, which are marketed under the YI brand. AMC Robotics is also engaged in developing additional hardware products and technology capabilities, including IoT-enabled devices, AI-based features, wearable devices, and AI robotics. Using its technological capabilities, the company is developing robotic dogs, robotic arms, and robotic unloading systems, offering smart solutions for the logistics and warehousing sectors. It has two primary operating segments: North America, which generates maximum revenue, and Europe.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.